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Abstract
The highly potent and kappa-opioid receptor (KOR)-selective hallucinogen salvinorin A and
selected analogs have been analyzed using the 3D quantitative structure-affinity relationship
technique Comparative Molecular Field Analysis (CoMFA) in an effort to derive a statistically
significant and predictive model of salvinorin affinity at the KOR and to provide additional
statistical support for the validity of previously proposed structure-based interaction models. Two
CoMFA models of salvinorin A analogs substituted at the C-2 position are presented. Separate
models were developed based on the radioligand used in the kappa-opioid binding assay,
[3H]diprenorphine or [125I]6β-iodo-3,14-dihydroxy-17-cyclopropylmethyl-4,5α-epoxymorphinan
([125I]IOXY). For each dataset, three methods of alignment were employed: a receptor-docked
alignment derived from the structure-based docking algorithm GOLD, another from the ligand-
based alignment algorithm FlexS, and a rigid realignment of the poses from the receptor-docked
alignment. The receptor-docked alignment produced statistically superior results compared to
either the FlexS alignment or the realignment in both datasets. The [125I]IOXY set (Model 1) and
[3H]diprenorphine set (Model 2) gave q2 values of 0.592 and 0.620, respectively, using the
receptor-docked alignment, and both models produced similar CoMFA contour maps that reflected
the stereoelectronic features of the receptor model from which they were derived. Each model
gave significantly predictive CoMFA statistics (Model 1 PSET r2 = 0.833; Model 2 PSET r2 =
0.813). Based on the CoMFA contour maps, a binding mode was proposed for amine-containing
salvinorin A analogs that provides a rationale for the observation that the β-epimers (R-
configuration) of protonated amines at the C-2 position have a higher affinity than the
corresponding β-epimers (S-configuration).
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Salvinorin A (Fig. 1) is a highly potent and selective kappa-opioid receptor (KOR) agonist
and the most potent naturally-occurring hallucinogen known [1]. The terpenoid was first
isolated from the plant Salvia divinorum and characterized by Ortega [2] in 1982. The same
compound was later isolated from S. divinorum by Valdes [3] in 1984 who reported its
psychoactive properties in mice. S. divinorum has been used for centuries by the Mazatec
Indians of Mexico for divination and is indigenous to a small area in the Sierra Mazateca
Mountains. The plant was subsequently propagated and can now be found growing in
widespread locations, sold by nurseries, and sold through the Internet for its hallucinogenic
properties as both dried leaves and fortified plant extracts. The FDA has yet to schedule
salvinorin A, its extracts, or dried leaves as a controlled substance, although many countries
and several states within the United States have adopted legislation banning the use of S.
divinorum and related products.
Since the discovery that salvinorin A is a remarkably potent and selective KOR agonist [1],
a large number of analogs have been synthesized, especially C-2 position analogs [4-19]. A
smaller number of C-4 position analogs [4,5,7,19-21] and analogs with alterations of the
furan ring [15,22,23] have also been reported in the literature. By inspection, the data
suggest that very little change is tolerated at the C-4 position or the furan ring. Thus,
attention was focused on C-2 modified structures for which a wide range of affinities have
been reported.
Salvinorin A is unique among hallucinogens in that its chemical structure lacks a basic
amine group. This is significant because such a moiety was previously thought to be
required for high ligand affinity at aminergic and other closely-related G Protein-Coupled
Receptors (GPCRs). It is generally understood that the receptor-ligand interaction involving
the amine is mediated by a conserved aspartate residue (D3.32) on transmembrane helix 3
(TM3) through formation of a hydrogen-bonded salt bridge, anchoring the ligand in the
binding site. Thus it is quite surprising that salvinorin A's high affinity for the KOR is
comparable to that of amine-containing ligands [24].
The molecular mechanisms by which salvinorin A achieves its exquisite affinity and
selectivity for the KOR is an active and ongoing area of research. Our working hypothesis is
that by removing the amine from a ligand, its affinity for the many aminergic and related
receptors decreases dramatically, resulting in high selectivity. That is, without the amine
“anchor”, the receptor becomes more sensitive to changes in the ligand structure, and
therefore the stereoelectronic nature of the ligand and its complementarity to the target
receptor become much more important factors in determining the affinity of the ligand for
the receptor.
Although the affinity of hundreds of salvinorin A analogs for the KOR has been reported,
there is very little published information regarding the QSAR of these compounds. In 2006,
Singh et al. [25] described a quantitative and predictive structure-affinity model derived
using a KOR homology model and virtual screening techniques with a set of a set of 27
salvinorin A analogs with modifications at the C-1, C-2, C-4 and C-17 positions. In the same
year, Pandit et al. [26] reported a CoMFA model for C-2 position salvinorin A analogs,
though the details of this study have yet to be published.
Comparative Molecular Field Analysis (CoMFA), a three-dimensional quantitative
structure-activity relationship (3D-QSAR) methodology, may be used to rationalize and
predict ligand-receptor interactions when used in conjunction with homology modeling. In
CoMFA, a 3D-QSAR model is constructed by correlating regions of steric and electrostatic
fields with experimentally obtained affinity data for a set of aligned ligands (the training set
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or TSET). Information contained in the model can then be used for the design and prediction
of binding affinities of new ligands (the prediction set or PSET) for the target receptor. The
resulting models are critically dependent on the ligand alignment method used. If receptor
structure-based ligand docking is used to generate the alignment, statistical 3D-QSAR
methods like CoMFA may be used to complement and provide additional statistical support
for the proposed ligand binding modes. Salvinorin A analogs are well-suited for a CoMFA
study because the core of the molecule does not vary and it is conformationally constrained
due to its polycyclic structure, much like the steroid system presented in the initial
description of the method [27].
We report here our successful generation of statistically significant and predictive CoMFA
models describing the interaction of C-2 salvinorin A analogs with the KOR and our use of
these models to propose a binding mode for C-2 amine-containing salvinorin A analogs.
2. Experimental methods
2.1. Receptor and ligand structures
CoMFA studies were performed using SYBYL software (version 7.3, Tripos Associates, St.
Louis, MO) on an HP xw9400 workstation running Red Hat Enterprise Linux 4. The hKOR
model used here was built based on the coordinates of activated bovine rhodopsin crystal as
previously described [24,28,29]. Compounds were constructed using the crystal structure [2]
of Salvinorin A, (Cambridge Structural Database code = BUJJIZ) as the template and then
energy-minimized using the Tripos Force Field (Gasteiger-Hückel charges; distance-
dependent dielectric constant = 4.0 D/Å; default parameters elsewhere).
2.2. Ligand docking and alignment
To explore the effect of ligand superimposition on the resulting statistical models, three
methods of alignment were employed in each study. In the first, the automated docking
routine GOLD was used to produce an alignment based on docked solutions of ligands to a
previously described model [24,28,29] of the KOR. Thus, the ligand ensemble is that
produced by docking with no explicit ligand-ligand atom superposition performed. The
second, a ligand-based method, was obtained using FlexS [30]. The third alignment method
was a rigid realignment of the receptor-docked alignment.
Docking of salvinorin compounds was performed using GOLD (version 4.0, Cambridge
Crystallographic Data Center, Cambridge, UK) as previously described [24,28,29]. Ten
docking runs were performed for each compound in the dataset. The initial alignment was
generated by selecting the docked solution in which a) a furan oxygen-Q1152.60 H-bond was
present and b) the stereochemical interactions appeared most reasonable for each ligand. In
most cases the chosen pose was the top-ranked solution. This resulted in an alignment that
resembled the previously-postulated model of Salvinorin A in the KOR [24,28,29] (Fig. 2).
The second alignment method (using the same dataset) was performed with FlexS (version
1.20.3, BioSolveIT GmbH, Sankt Augustin, Germany). FlexS aligns the conformation and
orientation of a ligand molecule relative to a reference molecule (template) that is treated as
rigid. The molecule to be superimposed is partitioned into fragments. An ‘anchor fragment’
is placed first and the remaining fragments are added iteratively, allowing conformational
flexibility at each step [30]. Compound 4 was used as the template for this alignment
because it is the longest C-2 chain that still retains high affinity. The third alignment
method, a realignment of the docked poses in the receptor-docked alignment, was performed
by aligning all compounds to salvinorin A using the SYBYL fit-atoms method. Carbon
atoms C-2, C-4 and C-5 of salvinorin A and the analogous atoms of each analog were
selected for the fitting process.
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The quality and nature of the data used to construct the CoMFA model is of prime
importance in obtaining an accurate, predictive model. Binding affinity data can vary from
lab to lab depending on the assay methods, radioligand and cell lines employed. The choice
of radiolabeled ligand can dramatically affect the values obtained [31,32], as can the level of
gene expression that results in differing receptor densities in cloned cell lines [33].
Therefore pooling of data for a CoMFA study is generally discouraged. In this work, two
independent CoMFA studies were undertaken, one in which [125I]IOXY (6β-iodo-3,14-
dihydroxy-17-cyclopropylmethyl-4,5α-epoxymorphinan) was used as the assay radioligand
and a second in which [3H]diprenorphine was the assay radioligand.
Compounds that are protonated at physiological pH (e.g. amines) and compounds with Ki >
1,000 nM were not included in the dataset. Protonated compounds would, perhaps, form an
ion-pair interaction with D1383.32 (Ballesteros-Weinstein numbering system [34,35]) of
transmembrane helix 3 (TM3) or E209xl2.49 of the extracellular loop 2 (EL2) that may result
in a significant difference in the binding mode compared to that of Salvinorin A. MOPAC
charges (AM1) were then applied to each aligned dataset before initiating the CoMFA
analyses. Training set compounds were chosen randomly with the only criterion being that
they cover a wide range of Ki values.
2.4. CoMFA model generation
In the 3D-QSAR analysis, all aligned training set (TSET) molecules are placed in a cubic
lattice (grid) that is divided into hundreds (or thousands) of points at a regular spacing. In
this CoMFA study, the default grid spacing of 2.0 Å was used. Lennard-Jones 6-12 and
Coulomb potentials were used to calculate the steric and electrostatic interaction fields,
respectively. An sp3-hybridized carbon atom with a charge of +1 was used as the probe
atom. The standard default settings were used, except for the steric and electrostatic cutoff
values that were each varied by increments of 5 kcal/mol from 10 to 50 kcal/mol in order to
obtain the highest value of q2 for each dataset alignment. All Ki data were converted to pKi
(–log Ki). The pKi represents the dependent variable while the CoMFA field potentials at
each grid point represent the independent variables in the partial least squares (PLS)
regression analyses. The standard “leave-one-out” (LOO) cross-validation method was used
to obtain the predictive correlation coefficient q2 and the optimal number of principal
components (PCs). In the LOO method, each compound is excluded one at a time. A model
is then constructed from the remaining compounds to predict the activity of the excluded
compound. The optimal number of PCs chosen corresponds to the smallest error of
prediction and the highest q2. The PLS analysis was then repeated with no validation using
the optimal number of PCs to generate the CoMFA model. The r2 statistic, which is a
measure of the amount of variation in the dependent variable that can be ascribed to
variation in the independent variable, and the standard error of estimate (SEE) were obtained
from this model. The r2pred was obtained from the linear regression of the experimental vs.
predicted pKi values of the prediction set (PSET). A column filter of 3 or 4 kcal/mol was
applied to improve efficiency and reduce noise in the field data. The filter procedure
excludes those columns whose grid point potentials vary below the set cutoff. In the first
model, region focusing [36] was used to improve the model statistics. Region focusing
divides the lattice grid into multiple grids with smaller lattice spacing and then performs a
CoMFA analysis on each grid. Grids below a determined q2 cutoff are eliminated and
another CoMFA analysis is performed on the remaining grids as a whole resulting in
enhancement of those lattice points and, in some cases, an improved statistical outcome.
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3. Results and discussion
3.1 Salvinorin A–KOR interaction model
Salvinorin A consists of a rigid hydrophobic core that contains eight hydrogen-bond
accepting oxygen atoms. In the postulated model of Salvinorin A docked in the hKOR as
recently described [24] (Fig. 2), the oxygen of the furan ring may form a hydrogen bond
with both Q1152.60 and Y3207.43. A hydrogen bond interaction with these two residues is
supported by site-directed mutagenesis studies [24,29,37] in which KOR mutants Q115A,
Y320A and Y320F all showed a substantial decrease in the binding affinity of salvinorin A
as compared to wild type KOR. An additional hydrogen bond may possibly exist between
Y3127.35 and the methoxy oxygen of the C-4 position methyl ester, although the KOR
mutants Y312A and Y312F showed only a modest decrease [29,37] in the binding affinity of
salvinorin A (4.5-fold decrease for the KOR Y312A mutant [37]). In addition, there is a
likely hydrophobic interaction between Y3137.36 and the methyl group of the C-2 position
acetoxy moiety of Salvinorin A that is supported by site-directed mutagenesis studies
[29,37] in which there are substantial losses of affinity for the KOR Y313A mutant but little
or no loss for the Y313F mutant (indicating a hydrophobic interaction rather than a
hydrogen bond interaction). Chimeric receptor studies [28,37,38] also highlight the
importance of residues in TM2 and TM7 in the binding of salvinorin A to the KOR. In
addition, substituted cysteine accessibility method (SCAM) studies [24,28,29] indicate that
these residues are accessible in the binding pocket. Finally, the putative salvinorin A binding
mode is consistent with recently-reported affinity labeling experiments that indicate that the
C-2 substituent in near TM7 [39].
It is perhaps useful to compare the KOR receptor homology model employed here with that
of the more recently determined β2-adrenoceptor crystal structure. Although the KOR model
was based on activated bovine rhodopsin as a template (PDB ID = 2I37) [40], several
modifications were applied during the course of model refinement. The two most notable of
these in terms of the conformation of the KOR binding site are briefly described here. First,
extracellular loop 2 (EL2) was repositioned using molecular dynamics to a location nearer to
the extracellular opening of the receptor [29], enlarging the binding site cavity. Although it
has been suggested that the EL2 loop be removed for purposes of ligand docking [41], there
is evidence that EL2 may in fact interact with salvinorin A [24]. Second, the extracellular
portion of TM2 was rotated [28] to bring the model in line with mutagenesis data that
suggests that, along with other mutations, Q1152.60 may interact with salvinorin A [37,38].
As a result, the conformation of the refined KOR model differs as much compared to the
original template as to the β2-adrenoceptor (PDB ID = 2RH1), consistent with the
suggestion that homology models of the opioid receptors would be among those that would
benefit most from the determination of the structure of a GPCR not closely related to those
currently available [42].
3.2 Alignment methods
One can make the assumption that the salvinorin analogs would bind in the same way as
Salvinorin A since the core of the molecule, in most cases, remains identical. If this is the
case, then methods such as FlexS or an atom-to-atom fit that result in a “tight” alignment of
molecules (low RMSD values for those atoms in the common core structure) might be
expected to result in a good CoMFA model. However, it was found that the receptor-docked
alignment, in which many of the molecules’ docked position and/or orientation deviated
from Salvinorin A (some by as much as 4.5 Å), was found to be superior to FlexS and the
realignment. In fact, in previous work (data not shown), several alignment methods available
in the SYBYL package were evaluated including manual atom fitting, database alignment,
GALAHAD and Surflex-Sim that resulted in well-aligned molecules but gave poor CoMFA
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statistics. Salvinorin A analogs may thus bind in a similar, but non-identical manner to the
parent. Accordingly, a receptor-docked alignment may provide a better picture for predictive
purposes, since the noted variability in the position of the rigid core represents the receptor's
ability to recognize and accommodate (up to a point) ligand analogs with sidechains of
varying size.
A rigid realignment of the docked poses was performed in order to evaluate which type of
alignment is more predictive: the alignment based on the receptor's perspective (the
receptor-docked alignment) or one based on the ligand's perspective (the realignment) [43].
This realignment resulted in the core of the molecules being very well aligned but exhibited
the poorest CoMFA statistics of the three types of alignments: FlexS, receptor-docked or
realigned (results not shown).
3.3. CoMFA results for the [125I]IOXY dataset
The [125I]IOXY dataset consisted of 34 salvinorin A analogs in which [125I]IOXY was used
as the assay radioligand for the determination of affinity (Table 1). This dataset was divided
into a TSET of 23 compounds and a PSET of 11 compounds. The three alignments
employed are shown in Fig. S1. Although the use of FlexS results in a “tighter” alignment of
the molecules (i.e. lower RMSD for the scaffold atoms), this alignment gave statistically
poorer results (q2 = 0.311) as compared to the model based on the receptor-docked
alignment (Model 1; region-focused q2 = 0.592) for the identical training sets. Region
focusing did not improve the FlexS model statistics in this case. The realigned set of
molecules, exhibiting the „tightest’ fit, resulted in a q2 = 0.526 after region focusing but a
poor r2 = 0.767. Predicted pKi values were also poor for the FlexS alignment and
realignment resulting in 6 of the 34 compounds in the FlexS set and 8 of the 34 compounds
in the realigned set having a residual value (experimental pKi – predicted pKi) greater than
the desired range of ±0.50 pKi units (results not shown), whereas all values fell within the
desired range for the receptor-docked alignment (Table 1). It is hypothesized that the
receptor-docked alignment paints a “truer” picture of how ligands might bind to the receptor
site, resulting in a more accurate CoMFA contour map reflecting the residues surrounding
the molecule in its docked position.
Model 1 CoMFA statistics (receptor-docked alignment) are shown in Table 2. A statistically
significant (F = 465) and predictive (q2 = 0.592) model was obtained after region focusing,
indicating the robustness of the model. The model was shown to have predictive power
(PSET r2 = 0.833) and that the slopes of the TSET and PSET regression lines were both
close to the ideal value of 1.0. The linear regression plots for Model 1 training and predicted
datasets are shown in Fig. 3. The region-focused CoMFA contour maps are shown in Fig. 4.
A region of bulk tolerance (green) can be seen around the C-2 position (Fig. 4a) extending
approximately three carbons in length from the carbonyl carbon. The binding affinity data
indicates that affinity decreases sharply for esters with chain lengths larger than four carbons
in length at the C-2 position. This bulk tolerance region falls within a hydrophobic pocket
formed from Y3127.35, Y3137.36 and I3167.39; this pocket would not be expected to
accommodate long chain lengths of greater than four carbons. A region of bulk intolerance
can be seen behind the C-1 position and in the receptor; this is the region occupied by
extracellular loop 2 (EL2) near the disulfide bridge linking the EL2 with transmembrane
helix 3 (TM3). In the electrostatic contour map (Fig. 4b) several areas where
electronegativity enhances affinity (red) are positioned around the ester and carbonyl
oxygens of the molecule. A small area in which electropositive atoms on the ligand enhance
affinity (blue) can be seen on the β (above the plane of the paper) side of the C-2 position
ester group. In the receptor, this blue region is found to fall near the negatively charged
carboxylate moiety of E2976.58 on TM6.
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3.4. CoMFA results for the [3H]diprenorphine dataset
The [3H]diprenorphine dataset consisted of 47 compounds in which [3H]diprenorphine was
used as the assay radioligand (Table 3). Of these, 34 compounds were chosen for the TSET
with the remaining 13 compounds comprising the PSET. In this set of compounds, region
focusing did not enhance the statistics of the model with the receptor-docked alignment, but
did enhance the statistics of the FlexS-aligned compounds and the realignment of docked
compounds. Prediction of pKi values for the FlexS alignment, however, were very poor,
resulting in eleven outliers (predicted value > ±0.50 pKi units from the experimental value)
out of the 48 compounds. The q2 for the FlexS region-focused model was 0.502, whereas for
the receptor-docked alignment (Model 2; no region focusing) q2 = 0.620. The realigned
dataset, after region focusing, showed poor CoMFA statistics with q2 = 0.320 and resulted in
six outliers out of the 47 compounds in the dataset. These alignments are shown in Fig. S1
and the statistics for the receptor-docked model (Model 2) are reported in Table 2. The
linear regression plot for Model 2 is shown in Fig. 5, and the CoMFA contour maps are
shown in Fig. 6.
Model 2, like Model 1, is statistically significant (F = 395) and predictive (q2 = 0.620) and
was shown to predict the external test set well (PSET r2 = 0.813), with all predicted pKi
values no greater than 0.50 log units from the experimental value. It should be noted that
roughly 50% of the statistical outliers in the FlexS alignments (compounds 9 and 26 in
Model 1 and compounds 26, 36, 38, 54, 55, 59 and 62 in Model 2; Tables 1 and 3) were
compounds that did not superimpose well in the corresponding receptor-docked alignments.
This implies that these compounds might bind in an orientation that differs from that of
salvinorin A. However, the model is able to accommodate the similar but non-identical
binding modes of these compounds. Each binding mode is effectively recognized by the
same receptor binding site, which may be thought of as a sterically-bounded three-
dimensional arrangement of pharmacophoric features (H-bond acceptor and donor sites,
hydrophobic regions, etc.). With respect to 3-D QSAR, the particular orientation of the
ligands is relatively unimportant compared to the way in which the pharmacophoric features
align with one another within the series, and in the case of structure-based 3D-QSAR, how
well the pharmacophoric features of the ligands align with complementary features of the
receptor. In other words, a single 3-D QSAR model (such as CoMFA) is able to effectively
accommodate different orientations of structurally similar molecules. Nonetheless, when
comparing members of an analogous series of compounds, one would expect to see some
degree of similarity, and that is the case here.
Multiple binding modes for agonists comprising a series of structurally related compounds
would seem to be less likely than for antagonists since in addition to simply binding to the
receptor site, agonists must stabilize a particular receptor conformation (or conformations)
recognizable by a G protein. However, it has been proposed for the β2-adrenoceptor that the
structurally related compounds isoproterenol and salbutamol, each with agonist activity,
bind the receptor using different modes [44]. It is also possible that structurally related
agonists are able to bind to and stabilize discrete intermediate conformational states of the
flexible GPCR [45], with each exhibiting agonist activity. It is also possible that structurally
related agonists, binding through different modes of interaction, elicit similar but distinct
functional responses through functional agonism [46]; that is, different activated receptor
states (that are recognized by different G proteins) may be stabilized by different agonist
binding modes. Despite the conformational variability associated with functional agonism,
however, there appears to be common features that are associated with an activated
rhodopsin-like GPCR. These features include a movement of the intracellular portion of
TM6 away from the helical bundle (i.e. opening of the “ionic lock”), with a corresponding
inward movement of the extracellular part of TM6 into the ligand binding cavity, a transition
that is regulated to some extent by the rotameric states of key “toggle switch” residues [47].
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The proposed binding modes of the salvinorins described here each interact with the
extracellular end of TM6 (I2946.55 and E2976.58). These interactions may prevent the
movement of the extracellular end of TM6 away from the binding site, preventing the
closure of the ionic lock and serving to stabilize (not necessarily equivalent) activated forms
of the KOR.
The contour maps for Model 2 are qualitatively similar to those in Model 1. As in Model 1,
there is a region of bulk tolerance around the C-2 ester group and a region of bulk
intolerance behind it (Fig. 6a). In Fig. 6b, regions of enhanced affinity with electronegativity
(red) are seen near the oxygens of the C-2 position ester group and the C-1 carbonyl. The
largest area of electronegativity falls within potential H-bonding distance of H304 near the
extracellular region of TM7.
It has been shown that both the methyl and carbonyl moieties of the C-2 acetoxy group
contribute to the affinity of salvinorin A for the KOR [14]. Removal of the C-2 position
carbonyl group (resulting in the C-2 ethyl ether) reduced the Ki by 3.4-fold, and our KOR-
salvinorin A interaction model suggests that the C-2 acetoxy carbonyl oxygen atom may
hydrogen bond with the un-ionized acid form of E209xl2.49. Removal of the methyl group
(resulting in the C-2 formate ester) also produced a modest drop in affinity. Mutagenesis
studies have suggested that a hydrophobic interaction between the aforementioned methyl
group and Y3137.36 is present [29], and in general it seems to be important to have a
hydrophobic moiety at a terminal position of the C-2 substituent for optimal ligand affinity
[14]. At the same time, it has also been observed that the optimal length of the C-2 sidechain
corresponds to about five heavy atoms for C-2 ethers [8], alkoxymethyl ethers [14] and
esters [18], the maximum size that can be easily accommodated in the putative binding
pocket.
It has been suggested that the alkoxy-oxygen of the C-2 alkoxymethyl ethers contributes to
ligand binding through an H-bond interaction on the basis of the substantially reduced
affinity of both the methylthiomethoxy and fluoromethoxy analogs 70 and 71, since neither
sulfur nor fluorine are good H-bond acceptors. However, the reduced affinity of these
analogs may also be explained via an alternative binding mechanism. In the proposed
binding mode for the fluoromethoxy analog (71), the fluorine atom is situated very close to
the sidechain carboxylate group of E209xl2.49; the close proximity of two hard
electronegative atoms would thus be expected to adversely affect the ligand binding. In
contrast, many of the docked poses of the alkoxymethyl ethers place the more distal alkoxy-
oxygen away from any potential H-bonding functionality and in a sterically restricted region
of the binding site between Y3127.35 and Y3137.36. Perhaps because of steric
incompatibility, the KOR is predicted to recognize an alternate conformation of the
methylthiomethoxy analog (70) in which the C-2 terminal methyl group maintains the
interaction with Y3137.36, but the remainder of the C-2 sidechain is located in a sterically
less restricted region near the entrance of the binding site. The fused tricyclic salvinorin core
is also shifted toward TM5 when compared with the putative binding mode of salvinorin A
(1); however, the placement of the furan ring is unchanged. The KOR-salvinorin interaction
model presented here thus suggests that increased affinity is observed with several of the
alkoxymethyl ether derivatives because the oxygen atom not directly attached to the
salvinorin core serves simply as a flexible linker that allows the terminal hydrophobic group
to effectively interact with Y3137.36.
It has also been observed that while monomethylation at the acetal carbon of the C-2
alkoxymethyl ethers is tolerated, dimethylation at this position can reduce the binding
affinity by more than 100-fold (compare compounds 60 and 72) [14]. Examination of the
proposed binding mode of the dimethylated analog 72 shows that one of the methyl groups
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intersects the yellow CoMFA contour representing a region where steric bulk decreases
affinity (see Fig. 6). This yellow region corresponds to the backbone of the EL2 loop and the
E209xl2.49 sidechain.
Finally, it should be noted that all compounds in the analysis are predicted to have a pKi
value within 0.5 log units of the experimentally-determined value. This corresponds to no
more than about a 3-fold difference in the Ki values, which we consider to be a realistic
upper bound for the experimental error associated with the Ki determination. Roughly this
amount of variability has been demonstrated for salvinorin A under very similar reported
experimental conditions [14,48].
3.6. Prediction of a C-2 amine binding mode
There is a particularly interesting region of where an electropositive moiety enhances
affinity (blue) near the C-2 position carbonyl oxygen atom on the β-side of the molecule
(Fig. 6b). This region of electropositivity falls near E209xl2.49, which may explain the high
affinity of some amine containing analogs [7] not included in the TSET or PSET of the
models described here. Docking studies of these amines reveal that the positively charged
amine group likely interacts with E209xl2.49. An example of the highest-affinity amine 75
(Fig. 7), with a reported Ki of 2.3 nM [7], is shown docked in the KOR (Fig. 8).
The docked position of this amine is very similar to salvinorin A in our proposed model of
the salvinorin A–KOR complex (Figs. 1 and 2). In addition to the furan oxygen having
potential hydrogen bond interactions with both Q1152.60 and Y3207.43, the hydrogen
bonding interaction between Y3127.35 and the C-4 position methyl ester oxygen, there is a
hydrophobic interaction of the methyl groups of the isopropyl substituent with the aromatic
rings of both Y3127.35 and Y3137.36 and an ionic interaction between the positively charged
nitrogen and the negatively charged sidechain of E209xl2.49. It should also be noted that this
is the β-epimer (i.e. the R-configuration at the C-2 position). The corresponding α-epimers
(with the S-configuration) do not interact as well at all points mentioned here due in part to
the amine being directed away from E209xl2.49. This may explain the lower affinity of the α-
isomers in this series of amine analogs, whereas the trend shown by the esters, ethers and
amides is just the opposite with the α-epimer having the higher affinity. The α-N-
isopropylamine analog has a reported Ki of 17.6 nM [7].
4. Conclusions
In this study, two CoMFA models of salvinorin A analogs bound to the hKOR were
presented whose similar contour maps coincided with the presence of complementary amino
acid sidechains in the binding pocket. These models also demonstrated significant predictive
ability. Model 1 analogs used [125I]IOXY as the radioligand in the binding affinity assay
while Model 2 analogs used [3H]diprenorphine. The alignment that was found to produce
the most statistically significant model was a receptor-docked alignment when compared
with FlexS and manual realignment methods. Region focusing enhanced Model 1 but not
Model 2. The contour maps revealed a region of bulk tolerance allowing for approximately a
three-carbon chain from the ester carbonyl carbon. The expected enhancement of affinity
with increasing electronegativity was seen around the C-2 position ester oxygens and the
C-1 position carbonyl oxygen. An area of enhanced affinity corresponding to increased
electropositivity on the β-side of the molecule correlated well with our postulated docked
position of amine compounds in the KOR and may explain the trend for the α-isomer amines
to have a higher affinity than the corresponding β-isomer amines in the series. Further
mutagenesis studies on the key interacting residues could be done to support or refute the
postulated amine-analog binding mode.
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Stereo view of Salvinorin A docked in the kappa opioid receptor. Salvinorin A is shown in
ball and stick and colored according to atom type. Residues are colored magenta.
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Model 1 linear regression plots. Open circles with a solid regression line indicate the
training set and open triangles with a dashed regression line refer to the prediction set.
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Model 1 CoMFA contour maps. (a) Green and yellow contours show regions of steric
tolerance and intolerance, respectively. (b) Red and blue contours show regions where
negative and positive electrostatic potential, respectively, are favored.
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Model 2 linear regression plot. Open circles and a solid line represent the training set
regression. Open triangles and a dashed line show the prediction set regression.
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Model 2 CoMFA maps. The color scheme is the same as in Fig. 4.
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β-N-isopropylamine analog of Salvinorin A (75).
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Stereo view of the β-N-isopropylamine analog of Salvinorin A docked in the KOR.
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Table 2
CoMFA statistics for Models 1 and 2.
Model 1 Model 2
Parameter Initial Value Region-Focused Value Initial Value
Number of Compounds (TSET) 23 23 34
Steric cutoff (kcal/mol) 25.0 25.0 35.0
Electrostatic cutoff (kcal/mol) 35.0 35.0 30.0
Column filtering (kcal/mol) 3.0 4.0 3.0
Number of components 6 6 6
Cross-validated r2 (q2) 0.491 0.592 0.620
Correlation coefficient r2 (TSET) 0.991 0.994 0.989
Standard error of the estimate (SEE) 0.090 0.071 0.107
F statistic 283 465 395
Steric contribution (%) 34.3 39.3 35.4
Electrostatic contribution (%) 65.7 60.7 64.6
Number of Compounds (PSET) 11 11 13
Correlation coefficient r2 (PSET) 0.841 0.833 0.813
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